Evoking neuronal activity to improve the lives of Alzheimer’s patients
illustration of head wearing vr headset
Our novel therapy is designed to evoke specific brain wave activity with the potential to preserve brain structure, cognition, and function among patients living with Alzheimer’s disease. 
illustration of head wearing vr headset
Our intervention evokes specific brain wave activity with the potential to preserve brain volume, cognition, and function among patients living with Alzheimer’s disease. 
cognito vr headset
Cognito's headset design concept
We are leading a novel category of disease-modifying therapy in Alzheimer’s disease
illustration of person wearing vr headset
Developed with a novel mechanism of action
Research shows that Alzheimer's patients have abnormal neuronal activity in the brain. We're advancing a new way of treating Alzheimer's disease by targeting this abnormal activity.
illustration of head wearing vr headset
Promising results from our Phase 2 study
In our Phase 2 OVERTURE trial, significant slowing of disease progression was observed among treated patients through the preservation of cognition, daily function, and whole brain volume. No serious treatment-limiting adverse events were reported.
illustration of person wearing vr headset
Designed to fit into patient’s lives
Patients receive this non-invasive treatment from the comfort of their home for one hour each day.
cognito vr headset
Watch Video
Cognito's headset design concept
illustration of head wearing vr headset sideview
Why do the brain's electrical activities matter?
Neurons communicate through electric signals, creating rhythmic brain activity known as "brain waves." When groups of neurons start firing at the same time, distinct brain waves form at various ranges. One such range is gamma waves, which play an important role in learning and memory. In Alzheimer’s patients, gamma waves are altered, indicating impairment in normal brain function.a
illustration of head wearing vr headset
How does our treatment work?
Our novel therapy is designed to evoke gamma wave activity through non-invasive visual and auditory stimulation. In prior clinical studies, it slowed cognitive and functional decline and loss of brain structure among treated Alzheimer's patients.
Woman using the cognito VR headset
Cognito's headset design concept
cognito vr headset
Cognito's headset design concept
a woman knitting
a woman drawing
a man petting his doga woman smiling
Exploring treatment across multiple neurodegenerative diseases
Exploring treatment across multiple neurodegenerative diseases
Our treatment received the FDA Breakthrough Device Designation for the treatment of cognitive and functional symptoms associated with Alzheimer’s disease, and we are expanding our approach to many other indications.
Click to enlarge
It all started with a breakthrough from leading MIT neuroscientists
Press, publications & announcements
January 2, 2024
Noninvasive Gamma Sensory Stimulation May Reduce White Matter and Myelin Loss in Alzheimer’s Disease
December 12, 2023
Cognito study shows white matter growth, reduced myelin loss in Alzheimer’s patients after neuromod treatment
December 11, 2023
Cognito Therapeutics reports non-invasive neuromod data for treating Alzheimer’s
December 11, 2023
Cognito Therapeutics Phase 2 OVERTURE Study MRI Imaging Analysis Published in Journal of Alzheimer’s Disease
October 30, 2023
Cognito Therapeutics Appoints Christian Howell as Chief Commercial Officer
January 2, 2024
Noninvasive Gamma Sensory Stimulation May Reduce White Matter and Myelin Loss in Alzheimer’s Disease
December 12, 2023
Cognito study shows white matter growth, reduced myelin loss in Alzheimer’s patients after neuromod treatment
December 11, 2023
Cognito Therapeutics reports non-invasive neuromod data for treating Alzheimer’s
December 11, 2023
Cognito Therapeutics Phase 2 OVERTURE Study MRI Imaging Analysis Published in Journal of Alzheimer’s Disease
October 30, 2023
Cognito Therapeutics Appoints Christian Howell as Chief Commercial Officer
Citations
View
Close

a Mably AJ, Colgin LL. Gamma oscillations in cognitive disorders. Curr Opin Neurobiol. 2018 Oct;52:182-187. doi: 10.1016/j.conb.2018.07.009. Epub 2018 Aug 16. PMID: 30121451; PMCID: PMC6139067.